Skip to main content
Top
Published in: Internal and Emergency Medicine 2/2008

01-06-2008 | IM - Original

Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients

Authors: Melina Verso, Giancarlo Agnelli, Pieter W. Kamphuisen, Walter Ageno, Mario Bazzan, Antonio Lazzaro, Francesco Paoletti, Maurizio Paciaroni, Stefano Mosca, Sergio Bertoglio

Published in: Internal and Emergency Medicine | Issue 2/2008

Login to get access

Abstract

Deep vein thrombosis of upper limb is a common complication of CVC in patients with cancer. In these patients the risk factors for CVC-related thrombosis are not completely defined. The purpose of this study was to identify the risk factors for CVC-related thrombosis in patients included in a randomized, double-blind, placebo-controlled study aimed at assessing the efficacy and safety of enoxaparin for the prophylaxis of CVC-related thrombosis. CVC-related thrombosis was screened by mandatory venography after 6 weeks of study treatment. A number of patient baseline characteristics were assessed as potential risk factors for CVC-related deep vein thrombosis. Crude associations between risk factors and clinical outcomes were assessed by χ2 test or Fisher’s exact test. Multiple logistic regression analysis was used to identify independent risk factors. A CVC-related thrombosis was found in 50 out of 310 patients (16.1%). At multiple logistic regression analysis, CVC tip misplaced in the upper half of superior vena cava (OR 4.05, 95%CI 1.64–10.02), left-sided CVC insertion (OR 2.29, 95%CI 1.01–5.51) and chest radiotherapy (OR 7.01, 95%CI 1.42–34.66) were independent risk factors for thrombosis. In addition to these risk factors, the presence of distant metastases (OR 9.36, 95%CI 1.53–57.05) increased the risk of thrombosis in patients who received placebo. An inadequate position of the CVC tip, left-sided CVC insertion and chest radiotherapy are independent risk factors for CVC-related thrombosis in cancer patients. Patients with distant metastases have an increased risk for thrombosis in absence of antithrombotic prophylaxis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Agnelli G, Verso M (2006) Therapy insight: venous catheter-related thrombosis in cancer patients. Nat Clin Pract Oncol 3(4):214–222PubMedCrossRef Agnelli G, Verso M (2006) Therapy insight: venous catheter-related thrombosis in cancer patients. Nat Clin Pract Oncol 3(4):214–222PubMedCrossRef
2.
go back to reference Agnelli G, Verso M (2005) Thrombosis and cancer: clinical relevance of a dangerous liaison. Haematologica 90(2):154–156PubMed Agnelli G, Verso M (2005) Thrombosis and cancer: clinical relevance of a dangerous liaison. Haematologica 90(2):154–156PubMed
3.
go back to reference Verso M, Agnelli G (2003) Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21:3665–3675PubMedCrossRef Verso M, Agnelli G (2003) Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21:3665–3675PubMedCrossRef
4.
go back to reference Bern HM, Lokich JJ, Wallach SR et al (1990) Very low dose of warfarin can prevent thrombosis in central venous catheters: a randomized, prospective trial. Ann Inter Med 112:423–428 Bern HM, Lokich JJ, Wallach SR et al (1990) Very low dose of warfarin can prevent thrombosis in central venous catheters: a randomized, prospective trial. Ann Inter Med 112:423–428
5.
go back to reference Monreal M, Alastrue A, Rull M et al (1996) Upper extremity deep venous thrombosis in cancer patients with venous access devices. Prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 75:251–253PubMed Monreal M, Alastrue A, Rull M et al (1996) Upper extremity deep venous thrombosis in cancer patients with venous access devices. Prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 75:251–253PubMed
6.
go back to reference Karthaus M, Kretzschmar A, Kröning H et al (2006) A Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 17(2):289–296PubMedCrossRef Karthaus M, Kretzschmar A, Kröning H et al (2006) A Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 17(2):289–296PubMedCrossRef
7.
go back to reference Couban S, Goodyear M, Burnell M et al (2005) Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 23(18):4063–4069PubMedCrossRef Couban S, Goodyear M, Burnell M et al (2005) Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 23(18):4063–4069PubMedCrossRef
8.
go back to reference Geerts WH, Pineo GF, Heit JA et al (2004) Prevention of venous thromboembolism. Chest 126:338S–400SPubMedCrossRef Geerts WH, Pineo GF, Heit JA et al (2004) Prevention of venous thromboembolism. Chest 126:338S–400SPubMedCrossRef
9.
go back to reference Young AM, Begum G, Billingham LJ (2005) WARP-a multicentre, prospective, randomized controlled trial of thrombosis prophylaxis with warfarin in cancer patients with central venous catheters (CVCs). Ann ASCO Meet 2005; abstr no. 8004 Young AM, Begum G, Billingham LJ (2005) WARP-a multicentre, prospective, randomized controlled trial of thrombosis prophylaxis with warfarin in cancer patients with central venous catheters (CVCs). Ann ASCO Meet 2005; abstr no. 8004
10.
go back to reference Verso M, Agnelli G, Bertoglio S et al (2005) Enoxaparin for the prevention of venous thromboembolism associated with central vein catheters: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 23(18):4057–4062PubMedCrossRef Verso M, Agnelli G, Bertoglio S et al (2005) Enoxaparin for the prevention of venous thromboembolism associated with central vein catheters: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 23(18):4057–4062PubMedCrossRef
11.
go back to reference Cadman A, Lawrance JAL, Fitzsimmons L, Spencer-Shaw A, Swindell R (2004) To clot or not to clot? That is the question in central venous catheters? Clin Rad 59:349–355CrossRef Cadman A, Lawrance JAL, Fitzsimmons L, Spencer-Shaw A, Swindell R (2004) To clot or not to clot? That is the question in central venous catheters? Clin Rad 59:349–355CrossRef
12.
go back to reference Tesselaar ME, Ouwerkek J, Nooy MA, Rosendaal FR, Osanto S (2004) Risk factors for catheter-related thrombosis in cancer patients. Eur J Cancer 40:2253–2259PubMedCrossRef Tesselaar ME, Ouwerkek J, Nooy MA, Rosendaal FR, Osanto S (2004) Risk factors for catheter-related thrombosis in cancer patients. Eur J Cancer 40:2253–2259PubMedCrossRef
13.
go back to reference Eastridge BJ, Lefor AT (1995) Complication of indwelling venous access devices in cancer patients. J Clin Onc 13(1):233–238 Eastridge BJ, Lefor AT (1995) Complication of indwelling venous access devices in cancer patients. J Clin Onc 13(1):233–238
14.
go back to reference Timsit JF, Farkas JC, Boyer JM et al (1998) Central vein catheter-related thrombosis in intensive care patients. Incidence, risk factors and relationship with catheter-related sepsis. Chest 114:207–213PubMedCrossRef Timsit JF, Farkas JC, Boyer JM et al (1998) Central vein catheter-related thrombosis in intensive care patients. Incidence, risk factors and relationship with catheter-related sepsis. Chest 114:207–213PubMedCrossRef
15.
go back to reference Craft PS, May J, Dorigo A, Hoy C, Plant A (1996) Hickman catheters: left sided insertion, male gender and obesity are associated with an increased risk of complications. Aust NZ J Med 26:33–39 Craft PS, May J, Dorigo A, Hoy C, Plant A (1996) Hickman catheters: left sided insertion, male gender and obesity are associated with an increased risk of complications. Aust NZ J Med 26:33–39
16.
go back to reference Unal AE, Bayar S, Arat M, Ihhan O (2003) Malpositioning of Hickman catheters, left versus right sided attempts. Transfus Apheresis Sci 28:9–12CrossRef Unal AE, Bayar S, Arat M, Ihhan O (2003) Malpositioning of Hickman catheters, left versus right sided attempts. Transfus Apheresis Sci 28:9–12CrossRef
17.
go back to reference PetersenJ, Delaney JH, Brakstad MT, Rowbotham RK, Bagley CM (1999) Silicone venous access devices positioned with their tips high in the superior vena cava are more likely to malfunction. Am J Surg 178(1):38–41CrossRef PetersenJ, Delaney JH, Brakstad MT, Rowbotham RK, Bagley CM (1999) Silicone venous access devices positioned with their tips high in the superior vena cava are more likely to malfunction. Am J Surg 178(1):38–41CrossRef
18.
go back to reference McGee WT, Ackerman BL, Rouben LR, Prasad VM, Bandi V, Mallory DL (1993) Accurate placement of central venous catheters: a prospective, randomized, multicenter trial. Crit Care Med 21(8):1118–1123PubMedCrossRef McGee WT, Ackerman BL, Rouben LR, Prasad VM, Bandi V, Mallory DL (1993) Accurate placement of central venous catheters: a prospective, randomized, multicenter trial. Crit Care Med 21(8):1118–1123PubMedCrossRef
19.
go back to reference Puel V, Caudry M, Metayer P et al (1993) Superior vena cava thrombosis related to catheter malposition in cancer chemotherapy given through implanted ports. Cancer 72:2248–2252PubMedCrossRef Puel V, Caudry M, Metayer P et al (1993) Superior vena cava thrombosis related to catheter malposition in cancer chemotherapy given through implanted ports. Cancer 72:2248–2252PubMedCrossRef
20.
go back to reference Agnelli G, Verso M (2006) Is antithrombotic prophylaxis required in cancer patients with central venous catheters? No. J Thromb Haemost 4(1):14–15PubMedCrossRef Agnelli G, Verso M (2006) Is antithrombotic prophylaxis required in cancer patients with central venous catheters? No. J Thromb Haemost 4(1):14–15PubMedCrossRef
21.
go back to reference Luciani A, Clement O, Halimi P et al (2001) Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on doppler US. Radiology 220(3):655–660PubMedCrossRef Luciani A, Clement O, Halimi P et al (2001) Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on doppler US. Radiology 220(3):655–660PubMedCrossRef
22.
go back to reference Kearns PJ, Coleman S, Wehner JH (1996) Complications of long-term catheters: randomized trial of central vs. peripheral tip location. J PEN 20(1):20–24 Kearns PJ, Coleman S, Wehner JH (1996) Complications of long-term catheters: randomized trial of central vs. peripheral tip location. J PEN 20(1):20–24
23.
go back to reference Gould JR, Carloss HW, Skinner WL (1993) Groshong catheter-associated subclavian venous thrombosis. Am J Med 95(4):419–423PubMedCrossRef Gould JR, Carloss HW, Skinner WL (1993) Groshong catheter-associated subclavian venous thrombosis. Am J Med 95(4):419–423PubMedCrossRef
24.
go back to reference De Cicco M, Matovic M, Balestrieri L et al (1997) Central venous thrombosis: an early and frequent complication in cancer patients bearing long term silastic catheter. A prospective study. Thromb Res 86(2):101–113PubMedCrossRef De Cicco M, Matovic M, Balestrieri L et al (1997) Central venous thrombosis: an early and frequent complication in cancer patients bearing long term silastic catheter. A prospective study. Thromb Res 86(2):101–113PubMedCrossRef
25.
go back to reference Blom JW, Doggen CJM, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations and the risk of venous thrombosis. JAMA 293:715–722PubMedCrossRef Blom JW, Doggen CJM, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations and the risk of venous thrombosis. JAMA 293:715–722PubMedCrossRef
26.
go back to reference Randolph AG, Cook DJ, Gonzales CA, Andrew M (1998) Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials. Chest 113(1):165–171PubMedCrossRef Randolph AG, Cook DJ, Gonzales CA, Andrew M (1998) Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials. Chest 113(1):165–171PubMedCrossRef
27.
go back to reference Stephens LC, Haire WD, Tarantolo S et al (1997) Normal saline versus heparin flush for maintaining central venous catheter patency during apheresis collection of peripheral blood stem cell. Transfus Sci 18(2):187–193PubMedCrossRef Stephens LC, Haire WD, Tarantolo S et al (1997) Normal saline versus heparin flush for maintaining central venous catheter patency during apheresis collection of peripheral blood stem cell. Transfus Sci 18(2):187–193PubMedCrossRef
Metadata
Title
Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients
Authors
Melina Verso
Giancarlo Agnelli
Pieter W. Kamphuisen
Walter Ageno
Mario Bazzan
Antonio Lazzaro
Francesco Paoletti
Maurizio Paciaroni
Stefano Mosca
Sergio Bertoglio
Publication date
01-06-2008
Publisher
Springer Milan
Published in
Internal and Emergency Medicine / Issue 2/2008
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-008-0125-3

Other articles of this Issue 2/2008

Internal and Emergency Medicine 2/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine